DRNA Insider Trading Activity and SEC Form 4 Filings
DRNA insider trading summary
No open-market insider purchases or sales of Dicerna Pharmaceuticals Inc (DRNA) have been reported on SEC Form 4 in the past 12 months.
Latest DRNA insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Nov 18, 2021 | Bob D Brown | Chief Scientific Ofr., EVP R&D | Sell | $946K (24,936 @ $37.94) |
| Sep 17, 2021 | Bob D Brown | Chief Scientific Ofr., EVP R&D | Sell | $448K (21,250 @ $21.06) |
| Sep 17, 2021 | Ling Zeng | Chief Legal Officer & Sec'y | Sell | $29K (1,334 @ $21.47) |
| Sep 17, 2021 | Shreeram Aradhye | EVP & Chief Medical Officer | Sell | $44K (2,056 @ $21.47) |
| Aug 10, 2021 | Douglas Fambrough | President and CEO | Buy | $110K (5,000 @ $22.10) |
| Aug 10, 2021 | Marc D Kozin | Director | Buy | $71K (3,000 @ $23.66) |
| Aug 2, 2021 | Bob D Brown | Chief Scientific Ofr., EVP R&D | Sell | $311K (8,312 @ $37.38) |
| Jul 6, 2021 | James B Weissman | Chief Operating Officer & EVP | Sell | $1.2M (30,000 @ $39.09) |
| Jul 1, 2021 | Bob D Brown | Chief Scientific Ofr., EVP R&D | Sell | $270K (7,246 @ $37.30) |
| Jul 1, 2021 | Bob D Brown | Chief Scientific Ofr., EVP R&D | Sell | $40K (1,066 @ $37.85) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.